(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
3 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally...
Stats | |
---|---|
今日成交量 | 676.00 |
平均成交量 | 291.00 |
市值 | 67.53B |
EPS | €0 ( 2024-02-12 ) |
下一个收益日期 | ( €0 ) 2024-05-01 |
Last Dividend | €0.375 ( 2023-07-20 ) |
Next Dividend | €0 ( N/A ) |
P/E | 31.15 |
ATR14 | €0.696 (0.47%) |
Zoetis Inc 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Zoetis Inc 财务报表
Annual | 2023 |
营收: | €8.54B |
毛利润: | €5.98B (70.03 %) |
EPS: | €5.08 |
FY | 2023 |
营收: | €8.54B |
毛利润: | €5.98B (70.03 %) |
EPS: | €5.08 |
FY | 2022 |
营收: | €8.08B |
毛利润: | €5.63B (69.63 %) |
EPS: | €4.51 |
FY | 2021 |
营收: | €7.78B |
毛利润: | €5.47B (70.38 %) |
EPS: | €4.26 |
Financial Reports:
No articles found.
Zoetis Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.325 (N/A) |
€0.325 (N/A) |
€0.375 (N/A) |
€0.375 (N/A) |
€0.375 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.200 | 2020-01-16 |
Last Dividend | €0.375 | 2023-07-20 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 15 | -- |
Total Paid Out | €4.23 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.04 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.76 | |
Div. Directional Score | 7.97 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PHI1.DE | Ex Dividend Junior | 2023-05-11 | Annually | 0 | 0.00% | |
AWC.DE | Ex Dividend Junior | 2023-08-07 | Quarterly | 0 | 0.00% | |
HRPK.DE | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
SGF.DE | Ex Dividend Junior | 2023-06-29 | Annually | 0 | 0.00% | |
CHV.DE | Ex Dividend King | 2023-08-17 | Quarterly | 0 | 0.00% | |
KSC.DE | Ex Dividend Junior | 2023-05-11 | Annually | 0 | 0.00% | |
UBK.DE | Ex Dividend Junior | 2023-06-30 | Sporadic | 0 | 0.00% | |
DWS.DE | Ex Dividend Knight | 2023-06-16 | Annually | 0 | 0.00% | |
NEM.DE | Ex Dividend Knight | 2023-05-24 | Annually | 0 | 0.00% | |
AAG.DE | Ex Dividend Junior | 2023-06-16 | Sporadic | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.274 | 1.500 | 4.51 | 6.77 | [0 - 0.5] |
returnOnAssetsTTM | 0.164 | 1.200 | 4.53 | 5.44 | [0 - 0.3] |
returnOnEquityTTM | 0.488 | 1.500 | 5.68 | 8.53 | [0.1 - 1] |
payoutRatioTTM | 0.295 | -1.000 | 7.05 | -7.05 | [0 - 1] |
currentRatioTTM | 3.36 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 1.770 | 0.800 | 4.30 | 3.44 | [0.8 - 2.5] |
cashRatioTTM | 1.079 | 1.500 | 5.11 | 7.67 | [0.2 - 2] |
debtRatioTTM | 0.473 | -1.500 | 2.12 | -3.18 | [0 - 0.6] |
interestCoverageTTM | 13.61 | 1.000 | 6.07 | 6.07 | [3 - 30] |
operatingCashFlowPerShareTTM | 5.11 | 2.00 | 8.30 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 3.52 | 2.00 | 8.24 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.352 | -1.500 | 4.59 | -6.89 | [0 - 2.5] |
grossProfitMarginTTM | 0.700 | 1.000 | 1.662 | 1.662 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.381 | 1.000 | 4.39 | 4.39 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.348 | 1.000 | 9.18 | 9.18 | [0.2 - 2] |
assetTurnoverTTM | 0.598 | 0.800 | 9.35 | 7.48 | [0.5 - 2] |
Total Score | 10.17 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 31.06 | 1.000 | 6.96 | 0 | [1 - 100] |
returnOnEquityTTM | 0.488 | 2.50 | 7.23 | 8.53 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 3.52 | 2.00 | 8.83 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.022 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 5.11 | 2.00 | 8.30 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.295 | 1.500 | 7.05 | -7.05 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.275 | 1.000 | 5.62 | 0 | [0.1 - 0.5] |
Total Score | 5.76 |
Zoetis Inc
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。